Novartis: completes acquisition of CAR-T cell therapy firm

(CercleFinance.com) - Novartis said it has now completed the acquisition of Endocyte, a US-based biopharmaceutical company focused on CAR-T therapies for cancer treatment.


The Swiss drugmaker said the acquisition will add an experimental therapy in Phase III development for metastatic castration-resistant prostate cancer, while strengthening its portfolio of nuclear medicines and radioligand therapies for treating cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.